Lisa Shulman is director of autism clinical services at the Children’s Evaluation and Rehabilitation Center at Montefiore Medical Center in New York City.
Lisa Shulman
Director of autism clinical services
Children’s Evaluation and Rehabilitation Center, Montefiore Medical Center
From this contributor
How to help underserved groups gain access to autism care
Place your autism center in the community you serve, remove barriers to care, cast a wide net for autism signs, and do as much as possible in the first visit: These principles can help build a lifelong relationship with the community.
How to help underserved groups gain access to autism care
By
Lisa Shulman
15 January 2019 | 6 min read
Children who ‘recover’ from autism still struggle
Some children with autism lose their diagnosis over time, but still struggle with language, learning and anxiety, says Lisa Shulman.
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
By
Lauren Schneider
4 February 2026 | 7 min read
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
By
Claudia López Lloreda
3 February 2026 | 4 min read
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
By
Calli McMurray
3 February 2026 | 6 min read